Carolyn Runowicz

Carolyn Runowicz

Auto-generated profile, based on publicly available information

Carolyn Runowicz

Florida International University Herbert Wertheim College of Medicine, Miami, Florida, USA

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
LTLindsey A. Torre
Lindsey A. Torre
BTBritton Trabert
Britton Trabert
CDCarol E. DeSantis
Carol E. DeSantis
KMKimberly D. Miller
Kimberly D. Miller
GSGoli Samimi
Goli Samimi
RSRebecca L. Siegel
Rebecca L. Siegel
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population‐based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non‐Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non‐Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5‐year cause‐specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5‐year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284–296 . © 2018 American Cancer Society .

16 November 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BFBernard Fisher
Bernard Fisher
JCJoseph P. Costantino
Joseph P. Costantino
DWD. Lawrence Wickerham
D. Lawrence Wickerham
RCReena S. Cecchini
Reena S. Cecchini
WCWalter M. Cronin
Walter M. Cronin
NWNorman Wolmark
Norman Wolmark
Background: Initial findings from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (P-1) demonstrated that tamoxifen reduced the risk of estrogen receptor–positive tumors and osteoporotic fractures in women at increased risk for breast cancer. Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings. Methods: Women (n = 13 388) were randomly assigned to receive placebo or tamoxifen for 5 years. Rates of breast cancer and other events were compared by the use of risk ratios (RRs) and 95% confidence intervals (CIs). Estimates of the net benefit from 5 years of tamoxifen therapy were compared by age, race, and categories of predicted breast cancer risk. Statistical tests were two-sided. Results: After 7 years of follow-up, the cumulative rate of invasive breast cancer was reduced from 42.5 per 1000 women in the placebo group to 24.8 per 1000 women in the tamoxifen group (RR = 0.57, 95% CI = 0.46 to 0.70) and the cumulative rate of noninvasive breast cancer was reduced from 15.8 per 1000 women in the placebo group to 10.2 per 1000 women in the tamoxifen group (RR = 0.63, 95% CI = 0.45 to 0.89). These reductions were similar to those seen in the initial report. Tamoxifen led to a 32% reduction in osteoporotic fractures (RR = 0.68, 95% CI = 0.51 to 0.92). Relative risks of stroke, deep-vein thrombosis, and cataracts (which increased with tamoxifen) and of ischemic heart disease and death (which were not changed with tamoxifen) were also similar to those initially reported. Risks of pulmonary embolism were approximately 11% lower than in the original report, and risks of endometrial cancer were about 29% higher, but these differences were not statistically significant. The net benefit achieved with tamoxifen varied according to age, race, and level of breast cancer risk. Conclusions: Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer. Readily identifiable subsets of individuals comprising 2.5 million women could derive a net benefit from the drug.

20 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CRCarolyn D. Runowicz
Carolyn D. Runowicz
CLCorinne R. Leach
Corinne R. Leach
NHN. Lynn Henry
N. Lynn Henry
KHKaren S. Henry
Karen S. Henry
HMHeather T. Mackey
Heather T. Mackey
PGPatricia A. Ganz
Patricia A. Ganz
The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. Copyright © 2015 American Cancer Society and American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.

7 December 2015 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
CRCarolyn D. Runowicz
Carolyn D. Runowicz
CLCorinne R. Leach
Corinne R. Leach
NHN. Lynn Henry
N. Lynn Henry
KHKaren S. Henry
Karen S. Henry
HMHeather T. Mackey
Heather T. Mackey
PGPatricia A. Ganz
Patricia A. Ganz

1 November 2002 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
DSDebbie Saslow
Debbie Saslow
CRCarolyn D. Runowicz
Carolyn D. Runowicz
DSDiane Solomon
Diane Solomon
AMAnna‐Barbara Moscicki
Anna‐Barbara Moscicki
RSRobert A. Smith
Robert A. Smith
CCCarmel Cohen
Carmel Cohen

1 January 2001 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
RSR. A. Smith
R. A. Smith
AEA. C. von Eschenbach
A. C. von Eschenbach
RWR. Wender
R. Wender
BLB. Levin
B. Levin
TBT. Byers
T. Byers
HEH. Eyre
H. Eyre
Updates to the American Cancer Society (ACS) guidelines regarding screening for the early detection of prostate, colorectal, and endometrial cancers, based on the recommendations of recent ACS worksh...